TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Brief Summary: The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i) peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary hypertension after pulmonary endarterectomy.


Options:
A: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: bosentan | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: tadalafil | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: tadalafil; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bosentan | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Brief Summary: The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i) peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary hypertension after pulmonary endarterectomy.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
B: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Riociguat (Adempas, BAY63-2521) up to 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Riociguat (Adempas, BAY63-2521) fixed 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2 mg | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 1 mg | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) fixed 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Brief Summary: The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH), to patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) because of (i) peripheral localization of thrombotic material or (ii) persistent or recurrent pulmonary hypertension after pulmonary endarterectomy.


Options:
A: Arm Label: STI571; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: All Patients; Type: EXPERIMENTAL; Interventions: Drug: Imatinib mesylate | Intervention Type: DRUG; Name: Imatinib mesylate; Assigned to Arm(s): All Patients, STI571 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aprocitentan 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 5 mg | Arm Label: Aprocitentan 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 10 mg | Arm Label: Aprocitentan 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 25 mg | Arm Label: Aprocitentan 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aprocitentan 50 mg | Arm Label: Lisinopril 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lisinopril 20 mg | Intervention Type: DRUG; Name: Aprocitentan 5 mg; Assigned to Arm(s): Aprocitentan 5 mg | Intervention Type: DRUG; Name: Aprocitentan 10 mg; Assigned to Arm(s): Aprocitentan 10 mg | Intervention Type: DRUG; Name: Aprocitentan 25 mg; Assigned to Arm(s): Aprocitentan 25 mg | Intervention Type: DRUG; Name: Aprocitentan 50 mg; Assigned to Arm(s): Aprocitentan 50 mg | Intervention Type: DRUG; Name: Lisinopril 20 mg; Assigned to Arm(s): Lisinopril 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: bosentan; Assigned to Arm(s): N/A
D: Arm Label: Part 1; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 2; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Drug: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently) | Arm Label: Part 3; Type: EXPERIMENTAL; Interventions: Drug: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose | Intervention Type: DRUG; Name: FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose; Assigned to Arm(s): Part 1, Part 2, Part 3 | Intervention Type: DRUG; Name: Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently); Assigned to Arm(s): Part 1, Part 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.
Brief Summary: The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.


Options:
A: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: A3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A4; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): A2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A3 | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): A4
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone
Brief Summary: The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes


Options:
A: Arm Label: Insulin degludec (IDeg); Type: EXPERIMENTAL; Interventions: Drug: insulin degludec | Arm Label: Insulin glargine (IGlar); Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): Insulin degludec (IDeg) | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): Insulin glargine (IGlar)
B: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: T2D, Dialysis, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Dialysis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): T2D, Dialysis, Liraglutide, T2D, Dialysis, Placebo, T2D, Normal kidney function, Liraglutide, T2D, Normal kidney function, Placebo
D: Arm Label: Saxagliptin 2.5 mg + Glyburide 7.5 mg (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Glyburide, Drug: Metformin | Arm Label: Saxagliptin 5 mg + Glyburide 7.5 mg (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Glyburide, Drug: Metformin | Arm Label: Placebo + Glyburide 7.5 mg (C); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Glyburide, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg + Glyburide 7.5 mg (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg + Glyburide 7.5 mg (B) | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Saxagliptin 2.5 mg + Glyburide 7.5 mg (A), Saxagliptin 5 mg + Glyburide 7.5 mg (B) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Glyburide 7.5 mg (C) | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Placebo + Glyburide 7.5 mg (C) | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Placebo + Glyburide 7.5 mg (C), Saxagliptin 2.5 mg + Glyburide 7.5 mg (A), Saxagliptin 5 mg + Glyburide 7.5 mg (B)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AMORCYTE MYOCARDIAL REPAIR STUDY- A Phase I Trial of Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction. (AMRS)
Brief Summary: Following a Heart attack the acute loss of heart muscle cells results in a cascade of events causing an immediate decrease in cardiac function that has the potential to persist long term. Despite revascularization of the infarct related artery circulation and appropriate medical management to minimize the stresses on the heart walls, a significant percentage of patients experience permanent cardiac dysfunction and consequently remain at an increased life-time risk of experiencing adverse cardiac events, including death.

There is a great potential for stem cell therapy, using a variety of cell precursors (particularly hematopoietic,)to contribute to new blood vessel formation (and possibly limited heart muscle formation) and muscle preservation in the myocardial infarct zone. The administration of cells via an infusion through the infarct related artery appears to be feasible and result in a clinical effect in some studies.

Therefore, we propose to evaluate the safety and efficacy of a CD34+ selected stem cell product (AMR-001), administered through the infarct related coronary artery 6 to 9 days after successful infarct related artery stent placement.

The primary objective of the study is to determine the feasibility and safety of prospectively identifying patients at risk for clinically significant cardiac dysfunction following a myocardial infarction and the ability to isolate and infuse via the affected coronary circulation an autologous bone marrow derived CD34+ cell product at four dose levels.

The secondary objective of the study is to assess the effect on cardiac function and infarct region perfusion. A concurrent patient group meeting eligibility but not receiving CD34+ cells will be evaluated similar to the treated group to assess the rate of significant spontaneous improvement in cardiac function without CD34+cell infusion.


Options:
A: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Intra-coronary infusion | Intervention Type: DRUG; Name: Intra-coronary infusion; Assigned to Arm(s): Treatment Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Adult stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Adult stem cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: intracoronary infusion of progenitor cells; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TeleCare Management of Pain and Depression in Cancer
Brief Summary: RATIONALE: Telemedicine may help in the treatment of depression and/or pain caused by cancer. It is not yet known whether telemedicine is more effective than standard care in treating depression and/or pain caused by cancer.

PURPOSE: This phase III randomized clinical trial is studying telemedicine to see how well it works compared to standard care in treating patients with depression and/or pain caused by cancer.


Options:
A: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1
C: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: Remote Arm; Type: N/A; Interventions: Device: The Medtronic CareLink system (Minneapolis, MN, USA). | Arm Label: Implantable defibrillator patients; Type: N/A; Interventions: Device: The Medtronic CareLink system (Minneapolis, MN, USA). | Intervention Type: DEVICE; Name: The Medtronic CareLink system (Minneapolis, MN, USA).; Assigned to Arm(s): Implantable defibrillator patients, Remote Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TeleCare Management of Pain and Depression in Cancer
Brief Summary: RATIONALE: Telemedicine may help in the treatment of depression and/or pain caused by cancer. It is not yet known whether telemedicine is more effective than standard care in treating depression and/or pain caused by cancer.

PURPOSE: This phase III randomized clinical trial is studying telemedicine to see how well it works compared to standard care in treating patients with depression and/or pain caused by cancer.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Arm 2
C: Intervention Type: BEHAVIORAL; Name: Disease Management Assessment; Assigned to Arm(s): N/A
D: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TeleCare Management of Pain and Depression in Cancer
Brief Summary: RATIONALE: Telemedicine may help in the treatment of depression and/or pain caused by cancer. It is not yet known whether telemedicine is more effective than standard care in treating depression and/or pain caused by cancer.

PURPOSE: This phase III randomized clinical trial is studying telemedicine to see how well it works compared to standard care in treating patients with depression and/or pain caused by cancer.


Options:
A: Arm Label: Core stabilization and psychosocial education; Type: EXPERIMENTAL; Interventions: Behavioral: Core stabilization and psychosocial education | Arm Label: Core stabilization exercise only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Core stabilization exercise only | Arm Label: Psychosocial education class only.; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychosocial education class only | Arm Label: Traditional Army training; Type: OTHER; Interventions: Behavioral: Traditional Army training | Intervention Type: BEHAVIORAL; Name: Traditional Army training; Assigned to Arm(s): Traditional Army training | Intervention Type: BEHAVIORAL; Name: Core stabilization exercise only; Assigned to Arm(s): Core stabilization exercise only | Intervention Type: BEHAVIORAL; Name: Psychosocial education class only; Assigned to Arm(s): Psychosocial education class only. | Intervention Type: BEHAVIORAL; Name: Core stabilization and psychosocial education; Assigned to Arm(s): Core stabilization and psychosocial education
B: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: Education and Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and standard care | Arm Label: Internet Mediated Enhanced Pedometer; Type: EXPERIMENTAL; Interventions: Other: Education and standard care, Behavioral: Internet mediated enhanced pedometer intervention | Intervention Type: OTHER; Name: Education and standard care; Assigned to Arm(s): Education and Standard Care, Internet Mediated Enhanced Pedometer | Intervention Type: BEHAVIORAL; Name: Internet mediated enhanced pedometer intervention; Assigned to Arm(s): Internet Mediated Enhanced Pedometer
D: Arm Label: web page; Type: ACTIVE_COMPARATOR; Interventions: Other: Webpage | Arm Label: Webpage and situational feedback; Type: EXPERIMENTAL; Interventions: Other: Webpage and situation feedback | Intervention Type: OTHER; Name: Webpage; Assigned to Arm(s): web page | Intervention Type: OTHER; Name: Webpage and situation feedback; Assigned to Arm(s): Webpage and situational feedback

Answer: B